These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 12064315)

  • 21. Fosamprenavir: a new PI option. Interview by Craig Sterritt.
    Nadler J
    IAPAC Mon; 2004 Feb; 10(2):50-2. PubMed ID: 15106520
    [No Abstract]   [Full Text] [Related]  

  • 22. Report from the 12th Retrovirus Conference. Adherence.
    Friedland GH; Nagy GS
    AIDS Clin Care; 2005 Apr; 17(4):36. PubMed ID: 15875309
    [No Abstract]   [Full Text] [Related]  

  • 23. Controversies in current treatment guidelines.
    Gazzard BG
    J HIV Ther; 2008 Mar; 13(1):1-3. PubMed ID: 18953266
    [No Abstract]   [Full Text] [Related]  

  • 24. Anti-HIV agents. Atazanavir and saquinavir.
    TreatmentUpdate; 2004; 16(3):9-10. PubMed ID: 17219610
    [No Abstract]   [Full Text] [Related]  

  • 25. Popping pills for life.
    Focus; 1998 Feb; 13(3):5-6. PubMed ID: 11365169
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-HIV drug update.
    Proj Inf Perspect; 2000 Aug; (30):5-6. PubMed ID: 12171015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Substitution for protease inhibitors in HIV therapy.
    Mikhail E
    N Engl J Med; 2003 Dec; 349(25):2460-1; author reply 2460-1. PubMed ID: 14689602
    [No Abstract]   [Full Text] [Related]  

  • 28. Editorial comment: a plethora or options in multidrug-resistant HIV-1 infection.
    Katzenstein DA
    AIDS Read; 2008 Sep; 18(9):478-9. PubMed ID: 18828232
    [No Abstract]   [Full Text] [Related]  

  • 29. Antiretroviral rounds. Putting resistance to work.
    Daar ES; Elion R
    AIDS Clin Care; 2004 Jul; 16(7):56, 60. PubMed ID: 15300926
    [No Abstract]   [Full Text] [Related]  

  • 30. Buffalo hump: what the experts suggest.
    Piliero PJ; McComsey GA
    AIDS Clin Care; 2004 Mar; 16(3):22-3. PubMed ID: 15119294
    [No Abstract]   [Full Text] [Related]  

  • 31. [Enduringly effective and tolerable initial therapy of HIV. Even after 5 years no resistance].
    MMW Fortschr Med; 2003 Dec; 145(50):60-1. PubMed ID: 14963980
    [No Abstract]   [Full Text] [Related]  

  • 32. Recent developments in antiretroviral therapy.
    DeSimone GA
    Clin J Oncol Nurs; 2001; 5(6):266, 275. PubMed ID: 11899628
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ICAAC clinical trials review available.
    AIDS Treat News; 2002 Oct; (384):5. PubMed ID: 12434763
    [No Abstract]   [Full Text] [Related]  

  • 34. WHO issues treatment guidelines for HIV/AIDS.
    AIDS Policy Law; 2002 May; 17(9):1. PubMed ID: 12030233
    [No Abstract]   [Full Text] [Related]  

  • 35. Drugs for HIV Infection.
    Treat Guidel Med Lett; 2004 Jan; 2(17):1-8. PubMed ID: 15529108
    [No Abstract]   [Full Text] [Related]  

  • 36. Virological suppression achieved with suboptimal adherence levels among South African children receiving boosted protease inhibitor-based antiretroviral therapy.
    Müller AD; Myer L; Jaspan H
    Clin Infect Dis; 2009 Jan; 48(1):e3-5. PubMed ID: 19025495
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiretroviral rounds. Resistance: what you don't know--can it hurt you?
    Gathe JC; Elion R
    AIDS Clin Care; 2008 Jun; 20(6):51-2. PubMed ID: 18661634
    [No Abstract]   [Full Text] [Related]  

  • 38. Efficacy and safety of once-daily antiretroviral therapy.
    Boyle BA
    AIDS Read; 2002 Mar; 12(3):90-2, 95-6, 109. PubMed ID: 11966243
    [No Abstract]   [Full Text] [Related]  

  • 39. DHHS issues adult guideline revisions.
    Bartlett JG;
    Hopkins HIV Rep; 2004 Jan; 16(1):1, 5. PubMed ID: 14989190
    [No Abstract]   [Full Text] [Related]  

  • 40. Editorial comment: tenofovir-related nephrotoxicity--who's at risk?
    Gupta Samir K
    AIDS Read; 2007 Feb; 17(2):102-3. PubMed ID: 17323509
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.